Alprazolam

Limits on what this shows

• Key negative/null findings: None located specific to this study within this review's tooling window; only the abstract-level detail was retrievable, not the full text, so complex-by-complex electron transport chain data (if reported) could not be independently confirmed.
• At-risk subgroups: Preclinical only; no human dosing or biomarker data exists to identify an at-risk human subgroup.
• Counter-evidence on record: None found; this is disclosed as a gap rather than a confirmed absence, since only one alprazolam-specific mitochondrial study was located in this review.

Regulatory status

Not addressed in the FDA label.

Population evidence

Zhu S, Shi J, Jin Q, et al. Mitochondrial dysfunction following repeated administration of alprazolam causes attenuation of hippocampus-dependent memory consolidation in mice. Aging (Albany NY). 2023. PMID 37801512. Combined in vitro (HT22 mouse hippocampal cell line exposed to alprazolam) and in vivo (mice given repeated alprazolam over 24 days) design. Alprazolam reduced mitochondrial membrane potential and induced apoptosis in HT22 cells; hippocampal neurons in vivo showed altered mitochondrial energy metabolism and morphology; brain-derived neurotrophic factor (BDNF) was significantly decreased on immunohistochemistry; proteomic analysis identified 439 differentially expressed proteins.

Mechanism

Named: alprazolam-induced reduction in mitochondrial membrane potential triggering apoptotic signaling in hippocampal neurons, with downstream BDNF reduction and impaired memory consolidation, the latter rescued by co-administration of the mitochondrial protector NSI-189.

Counter-evidence held on record

This is a mouse and cultured-cell study using repeated dosing over 24 days, not a human clinical finding, and it should not be read as evidence of mitochondrial disease risk from standard human anxiolytic or panic-disorder dosing. It is not a basis for mitochondrial-support supplementation.

Limits on what this shows

• Key negative/null findings: Baseline oxidative stress differed by underlying kidney disease status: healthy living donors had lower baseline values than the chronic-kidney-disease recipients before any premedication, a confounding-by-indication signal that the trial's control-group design only partly addresses. No fully drug-naive, non-perioperative outpatient arm was included, so chronic outpatient anxiolytic dosing was not tested by this study.
• At-risk subgroups: Perioperative transplant donors and recipients specifically. Generalizability to standard outpatient anxiolytic or panic-disorder dosing is not established by this trial.
• Counter-evidence on record: No second alprazolam-specific human oxidative-stress study, in either direction, was located in this review to corroborate or contest this single trial; its standing as the only orange-tier entry rests on one study, which is why it is bounded rather than red.

Regulatory status

Not addressed in the FDA label; no labeled redox or oxidative-stress warning exists for alprazolam.

Population evidence

Can MG, Ilgaz Kocyigit O, Aksu U, Ozer A, Toraman F. Effect of Alprazolam on Redox Status in Renal Transplantation Donors and Recipients. Ann Transplant. 2017. PMID 28596511. Randomized controlled trial, 82 participants across four groups (living kidney donors and their matched recipients, each with and without alprazolam premedication). Advanced oxidative protein products (AOPP), total thiol, and ischemia-modified albumin were measured at multiple perioperative timepoints. Oxidative stress parameters remained elevated in both the alprazolam-premedicated donor and recipient groups relative to their respective non-medicated control groups.

Mechanism

Not biochemically named by the authors; benzodiazepine GABA-A receptor binding is not a classical pro-oxidant pathway, and this trial did not propose one. Reported as an empirical redox-marker finding, not a confirmed mechanism.

Counter-evidence held on record

This finding is bounded to a single perioperative transplant-surgery context with a confounded baseline (donors versus chronic-kidney-disease recipients) and does not establish that routine outpatient alprazolam use raises oxidative stress. It is not a basis for antioxidant supplementation, and it should not be generalized beyond the transplant-premedication setting it was measured in.

Limits on what this shows

• Why no grade: The dual condition for ungraded requires no Tier B/C evidence and no circulating claim. The drug-specific half is confirmed clean; the class-level half could not be fully verified this session (see Channels tried), so this entry is disclosed as a gap with a named tooling limitation attached, not a fully closed-out null result.

Channels tried

PubMed, direct query "alprazolam copper": returned a clean, confirmed zero-result page ("your search was processed without automatic term mapping because it retrieved zero results"). A broader combined query, "alprazolam AND (iron OR copper OR ferritin OR hemoglobin OR hematocrit)," returned ten results (hemoglobin conformational change, glucose regulation in diabetes, redox status, an alprazolam/melatonin sleep comparator trial, an electrochemical biosensor paper, forensic toxicology), none addressing copper status. A follow-up class-level query, "benzodiazepine iron copper metabolism," was attempted on PubMed to check for any Tier C class support before defaulting to ungraded, but returned a reCAPTCHA bot-verification challenge page instead of results. The same query was retried on OpenAlex's search endpoint as an alternate channel per this protocol's own guidance, and that request returned an HTTP 429 rate-limit response from the host itself. No further alternate-host attempt was made given the time already spent on this single category.

Circulating-claim check

Drugs.com's alprazolam side-effects page and RxList's Xanax monograph were both checked directly; neither contains any copper or general mineral-depletion claim.

Assessment

The drug-specific channel gave a clean, confirmed zero, which is meaningful since the same broad query successfully surfaced real, relevant hits for other categories in this dossier (hemoglobin, oxidative stress). The class-level check is a genuine, disclosed tooling limitation, not a confirmed absence: a revision should re-run "benzodiazepine copper" against PubMed and OpenAlex's search endpoint once those channels are not rate-limited, before this entry can be called a fully confirmed gap rather than a partial one.

Limits on what this shows

• Why no grade: The dual condition for ungraded requires no Tier B/C evidence and no circulating claim. The drug-specific half is confirmed clean across two phrasings; the class-level half could not be fully verified this session (see Channels tried), so this entry is disclosed as a gap with a named tooling limitation attached.

Channels tried

PubMed, direct query "alprazolam iron deficiency": returned a clean, confirmed zero-result page ("no results were found"). The same combined query used for Copper, "alprazolam AND (iron OR copper OR ferritin OR hemoglobin OR hematocrit)," returned ten substantive results (see Copper entry above), none of which addressed iron status, ferritin, or transferrin. The class-level follow-up, "benzodiazepine iron copper metabolism," hit the same PubMed reCAPTCHA block described under Copper, and the OpenAlex search-endpoint retry hit the same HTTP 429 rate limit.

Circulating-claim check

Drugs.com's alprazolam side-effects page and RxList's Xanax monograph were both checked directly; neither contains any iron or anemia-related depletion claim (the label's own adverse-reaction tables also list no hematologic effects at all, see Oxygen delivery/utilization).

Assessment

The drug-specific channel gave a clean, confirmed zero across two independent phrasings, which is meaningful evidence of a genuine gap at that level. The class-level check remains a disclosed, unresolved tooling limitation from this review, not a confirmed absence, and should be re-tried in a future revision.

Limits on what this shows

• Key negative/null findings: Two separate PubMed phrasings ("alprazolam gut microbiome" and "benzodiazepine gut microbiota") were run and returned substantive, on-topic results for other drugs and drug classes, meaning the searches themselves worked; alprazolam simply was not among the drugs those results named.
• At-risk subgroups: None established for alprazolam; the flunitrazepam finding comes from an aquatic environmental-exposure model in a non-mammalian species, not oral human dosing.
• Counter-evidence on record: None found specific to alprazolam.

Regulatory status

Not addressed in the FDA label.

Population evidence

Class-level only. A PubMed search for "benzodiazepine gut microbiota" surfaced: Flunitrazepam induces neurotoxicity in zebrafish through microbiota-gut-brain axis, Sci Total Environ, 2023, PMID 37532048, an environmental-exposure ecotoxicology study in zebrafish, not a clinical human dosing study, using flunitrazepam, not alprazolam. A direct search for "alprazolam gut microbiome" returned two results, neither on-topic: a 2023 etifoxine (a non-benzodiazepine anxiolytic) human gut microbiome study, and a 2025 botanical liver-inflammation study in which alprazolam appears only as an incidental abstract mention, not as a microbiome endpoint for alprazolam itself.

Mechanism

Theoretical only: GABA-A receptor modulation is broadly plausible as a class-level mechanism for gut-brain-axis effects, but this is not demonstrated for alprazolam specifically, and flunitrazepam differs chemically from the triazolobenzodiazepine subclass alprazolam belongs to.

Counter-evidence held on record

This is the weakest form of class extrapolation in this dossier: a different molecule, a non-mammalian species, and an environmental waterborne-exposure route rather than clinical oral dosing. It should not be used to justify any probiotic, prebiotic, or microbiome-support recommendation for patients taking alprazolam.

Limits on what this shows

• Key negative/null findings: No direct ATP measurement was confirmed as present or absent from the full text in this review; this entry is graded on the mechanistic plausibility of the membrane-potential finding, not on a directly confirmed ATP assay.
• At-risk subgroups: None established in humans; preclinical only.
• Counter-evidence on record: None located.

Regulatory status

Not addressed in the FDA label.

Population evidence

Zhu S, Shi J, Jin Q, et al., 2023, PMID 37801512 (see Mitochondrial burden). The retrievable abstract-level summary describes "altered mitochondrial energy metabolism and morphology in the hippocampal neurons" in alprazolam-dosed mice, without a separately reported ATP quantification value.

Mechanism

Implied rather than directly demonstrated: a reduced mitochondrial membrane potential is the proximate driver of impaired ATP synthase function, but this study's retrievable detail describes energy metabolism and morphology changes descriptively rather than reporting a validated ATP yield assay.

Counter-evidence held on record

Descriptive language about "energy metabolism" in a mouse hippocampal study is not the same as a validated ATP assay, and this entry should not be read as confirmed evidence of impaired cellular energy output in humans. It is not a basis for any ATP-support supplement claim, and it shares its underlying source with Mitochondrial burden above (see Overlap map).

Limits on what this shows

• Key negative/null findings: The FDA label's complete absence of any hematologic adverse-reaction listing across both clinical-trial and postmarketing sections functions as population-scale negative evidence: no anemia, methemoglobinemia, or oxygenation-impairment signal has been picked up in labeled human use at any frequency the FDA considered worth listing.
• At-risk subgroups: None identified; the source is an in vitro structural-biology study with no clinical population.
• Counter-evidence on record: The label's clean hematologic adverse-reaction record (see Key negative/null findings) directly counters any suggestion that this in vitro binding finding translates into a clinical oxygen-delivery problem.

Regulatory status

The FDA label's adverse-reaction tables (clinical trials and postmarketing) list no hematologic adverse reactions, no anemia, and no hemoglobin- or hematocrit-related findings anywhere, confirmed by direct review of the current label.

Population evidence

Maitra S, Saha B, Santra CR, Mukherjee A, Goswami S, Chanda PK, Karmakar P. Alprazolam induced conformational change in hemoglobin. Int J Biol Macromol. 2006 (PMID 17207849). In vitro biophysical study using circular dichroism and fluorescence spectrometry on isolated hemoglobin exposed to alprazolam, demonstrating a structural (secondary/tertiary) conformational change on binding. This review could confirm the study's design, methods, and authorship independently but could not retrieve the full quantitative results (binding constant, stoichiometry) through the channels available.

Mechanism

Named at the structural level: direct ligand binding of alprazolam to hemoglobin altering its conformation, as detected by spectroscopic methods. No functional oxygen-affinity or oxygen-carrying-capacity assay is confirmed as included.

Counter-evidence held on record

A structural binding change to purified hemoglobin in a cuvette is not evidence of impaired oxygen delivery in a person, and per this protocol's own rules this must never be recast as a functional anemia or hypoxia claim. The label's clean hematologic record should be read alongside this entry, not omitted from it.